As shares of Valeant Pharmaceuticalsrallied nearly 9 percent after the company's earnings report, Chairman and CEO Joseph Papa joined CNBC's Jim Cramer to explain the move.
For the first time since 2015, we're seeing organic growth: Valeant Pharma CEO
Понравилась статья? Подпишитесь на канал, чтобы быть в курсе самых интересных материалов
Подписаться